ET is a chronic disease that may transform to MF

ET is an MPN characterized by thrombocytosis with bone marrow megakaryocytic hyperplasia and a tendency to develop thrombotic and hemorrhagic complications.1-3

In some patients, ET may transform into post-ET MF.4 ET can also transform into secondary acute myelogenous leukemia in a small minority of patients.5

MF=myelofibrosis; MPN=myeloproliferative neoplasm.

References: 1. Cervantes F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2011;2011:215-221. 2. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-166. 3. Tefferi A, Barbui T. Personalized management of essential thrombocythemia—application of recent evidence to clinical practice. Leukemia. 2013;27(8):1617-1620. 4. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res. 2010;16(7):1988-1996. 5. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-452.

Get key information for critical ET topics

Risk

Find out about the long-term prognosis for patients with ET and see which variables are associated with shortened survival.

Diagnosis

Review the most common signs and symptoms of ET and discover why diagnosis may be difficult.